Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
Breast J
; 25(2): 219-225, 2019 03.
Article
in En
| MEDLINE
| ID: mdl-30734437
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Furans
/
Ketones
/
Antineoplastic Agents
Type of study:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Limits:
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Breast J
Journal subject:
NEOPLASIAS
Year:
2019
Document type:
Article
Affiliation country:
España
Country of publication:
Estados Unidos